Abstracts tagged "dermatomyositis"

Abstract Number: 1556 • ACR Convergence 2020
Assessing Calcinosis in Dermatomyositis with Computed Tomography and Calcium Scoring
Prateek Gowda¹, Briana Cervantes², Lisa G. Rider³, Frederick W. Miller⁴, Marcus Chen⁴ and Adam Schiffenbauer⁴, ¹NIBIB, Baltimore, MD, ²NIEHS, Silver Spring, MD, ³Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a condition in which calcium salts are deposited in and around soft tissue and is observed in up to 30% of adult…
Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium
Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Sonia Savani¹, Natasha Ruth ², Paul Nietert ¹, Gabrielle Morgan ³, Mileka Gilbert ¹ and Lauren Pachman ⁴, ¹Medical University of South Carolina, Charleston, South Carolina, ²Medical University South Carolina, Charleston, South Carolina, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…
Abstract Number: 1290 • 2019 ACR/ARP Annual Meeting
Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Iago Pinal-Fernandez¹, Maria Casal-Dominguez ¹, Assia Derfoul ¹, Katherine Pak ¹, Paul Plotz ¹, Frederick W. Miller ², Jose C Milisenda ³, Josep M Grau-Junyent ³, Albert Selva-O'Callaghan ⁴, Julie Paik ⁵, Jemima Albayda ⁶, Lisa Christopher-Stine ⁷, Thomas E Lloyd ⁵, Andrea M Corse ⁵ and Andrew L Mammen ¹, ¹National Institutes of Health, Bethesda, ²NIEHS, NIH, Bethesda, MD, ³Clinic Hospital, Barcelona, ⁴Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain, Barcelona, ⁵Johns Hopkins, Baltimore, ⁶Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis…
Abstract Number: 1296 • 2019 ACR/ARP Annual Meeting
Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Majid Zeidi¹, Kristen Chen ¹, Basil Patel ², Rachel Lim ³ and Victoria Werth ¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia
Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing…
Abstract Number: 1866 • 2019 ACR/ARP Annual Meeting
Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Jessica Neely¹, Dmitry Rychkov ¹, Manish Paranjpe ¹, Michael Waterfield ², Susan Kim ¹ and Marina Sirota ², ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: Dermatomyositis (DM) is a complex immune-mediated disease resulting in muscle and skin inflammation. Prior studies of gene expression in DM have revealed a type…
Abstract Number: 1869 • 2019 ACR/ARP Annual Meeting
Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders
Kristen Chen¹, Majid Zeidi ¹, Maria Wysocka ², Nithin Reddy ¹, Arvin Jadoo ¹, Muhammad Bashir ¹, Sarah Ahmed ², Basil Patel ², Kevin Zhang ², Barbara White ³ and Victoria Werth ¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Dermatomyositis (DM) is an autoimmune disease affecting the skin, skeletal muscle, lungs, and/or other organs. While the pathogenesis remains poorly understood, it is thought…
Abstract Number: 1933 • 2019 ACR/ARP Annual Meeting
Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis
Jihad Aljabban¹, Saad Syed ², Sharjeel Syed ³, Kalyn Hoffman ⁴, Laith Hasan ⁵, Nikhil Adapa ¹, Zahir Allarakhia ⁶, Dexter Hadley ⁷, Mohamad Aljabban ⁸ and Wael Jarjour ⁹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴The Ohio State University College of Medicine, Columbus, OH, ⁵Tulane School of Medicine, New Orleans, ⁶Ohio State University College of Medicine, Columbus, OH, ⁷Institute for Computational Health Sciences, San Francisco, ⁸Genesys Health Systems, Grand Blanc, MI, ⁹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease-causing inflammatory changes in the skin and skeletal muscles. DM is associated with carcinomas of the ovary,…
Abstract Number: 1934 • 2019 ACR/ARP Annual Meeting
Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis
Jihad Aljabban¹, Sharjeel Syed ², Saad Syed ³, Zarife Sahenk ⁴, Noah Weisleder ⁵, Kevin McElhanon ⁵, Kalyn Hoffman ⁶, Nikhil Adapa ¹, Zahir Allarakhia ⁷, Laith Hasan ⁸, Dexter Hadley ⁹, Mohamad Aljabban ¹⁰ and Wael Jarjour ¹¹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, CA, ³Stanford School of Medicine, Stanford, ⁴Department of Neurology, Research Institute at Nationwide Children’s Hospital, Columbus, OH, ⁵Dorothy M. Davis Heart and Lung Research Institute & Dept. of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University College of Medicine, Columbus, OH, ⁷Ohio State University College of Medicine, Columbus, OH, ⁸Tulane School of Medicine, New Orleans, ⁹Institute for Computational Health Sciences, San Francisco, ¹⁰Genesys Health Systems, Grand Blanc, MI, ¹¹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease causing inflammatory changes to the skin and skeletal muscles. TRIM family proteins are composed of approximately…
Abstract Number: 93 • 2019 ACR/ARP Annual Meeting
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Amrutesh Puranik¹, Mark Jensen ², Regine Tipon ³, Yogita Ghodke-Puranik ³, Valeria Mezzano ⁴, Shanmugapriya Selvaraj ⁵, Theresa Wampler Muskardin ⁴, Cynthia Loomis ⁴, Ann Reed ⁶, Lauren Pachman ⁷ and Timothy Niewold ⁵, ¹NYU Langone Health, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴New York University Langone Health, New York, ⁵New York University Langone Health, New York, NY, ⁶Duke University School of Medicine, Durham, NC, ⁷Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: T and B cells come together in ectopic lymphoid aggregates in myositis, suggesting that local T:B cell interactions could play a role in disease. …
Abstract Number: 2739 • 2019 ACR/ARP Annual Meeting
Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
Mika Tabata¹, Kavita Sarin ², Karen Page ³, Christine Huard ³, Shanrong Zhao ³, Donald Bennett ³, Jillian Johnson ³, Kristen Johnson ³ and David Fiorentino ², ¹Stanford University School of Medicine, Stanford, CA, ²Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Pfizer, Boston
Background/Purpose: Interferon (IFN) signaling is upregulated in dermatomyositis (DM) and thought to play a role in pathogenesis. An IFN gene signature in peripheral blood of…
Abstract Number: 395 • 2019 ACR/ARP Annual Meeting
Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis
Soumyasri Kambhatla¹, Carrie Richardson ², Prasanth Lingamaneni ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: A subset of patients with dermatomyositis may fail to achieve remission despite treatment. Nevertheless, the risk factors for failure to achieve remission in dermatomyositis are largely…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Victoria Werth¹, David Pearson ², Joyce Okawa ², Rui Feng ³, Josef Concha ², Basil Patel ², Emily Hejazi ², Scott Constantine ⁴, Nancy Dgetluck ⁴ and Barbara White ⁴, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].